Purchase this article with an account.
O. Ustariz–Gonzalez, A. Suarez–Lincona, H. Quiroz–Mercado, J. Guerrero–Naranjo, A. Perez–Reguera, D. Moreno–Paramo, G. Alvarez–Rivera, A. Amaya–Espinosa, F. Furno–Sola; Bevacizumab Injection in Von Hippel Lindau Disease . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4713.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report safety and efficacy of intravitreal Bevacizumab (Avastin, Genetec. Inc) in two patients with Von Hippel Lindau Disease.
Two eyes of 2 patients were treated with intravitreal Bevacizumab. Complete ophthalmic evaluation, visual acuity and fluorescein angiography (FA) were evaluated before and after 3 months of follow–up.
Both patients increase their visual acuity. One patient from –1.40 to –1.00 LogMAR and the other from –1.40 to –0.80 LogMAR. Vitreous opacity by ophthalmoscopy and color photos decreased in both eyes and FA showed less leakage.
Intravitreal Bevacizumab was a safe treatment and decreased vascular permeability at 3 months follow–up.
This PDF is available to Subscribers Only